Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

Pharmacodynamics in Geriatric Patients: Effects of Age

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Accelerated epigenetic aging and inflammatory/immunological profile (ipAGE) in patients with chronic kidney disease.

GeroScience·2022

Same author

Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson's disease patients.

NPJ Parkinson's disease·2022

Same author

Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson's disease patients.

Scientific reports·2022

Same author

GDF15, an emerging key player in human aging.

Ageing research reviews·2022

Same author

Association of rs3027178 polymorphism in the circadian clock gene PER1 with susceptibility to Alzheimer's disease and longevity in an Italian population.

GeroScience·2021

Same author

An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging.

Nature aging·2021

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Quantification of Coenzyme A in Cells and Tissues

Quantification of Coenzyme A in Cells and Tissues

Published on: September 27, 2019

Paraoxonase 1: genetics and activities during aging.

Francesca Marchegiani¹, Maurizio Marra, Fabiola Olivieri

¹Center of Molecular Biology and Genetics, INRCA, Ancona, Italy. b.molecolare@inrca.it

Rejuvenation Research

|February 19, 2008

Summary

Paraoxonase 1 (PON1) is an enzyme crucial for protecting lipids from damage. Research suggests PON1 activity and genetic variations play a role in aging and human longevity by counteracting oxidative stress.

More Related Videos

Assessing Lysosomal Alkalinization in the Intestine of Live Caenorhabditis elegans

Assessing Lysosomal Alkalinization in the Intestine of Live Caenorhabditis elegans

Published on: April 13, 2018

Related Experiment Videos

Last Updated: Jul 7, 2026

Quantification of Coenzyme A in Cells and Tissues

Quantification of Coenzyme A in Cells and Tissues

Published on: September 27, 2019

Assessing Lysosomal Alkalinization in the Intestine of Live Caenorhabditis elegans

Assessing Lysosomal Alkalinization in the Intestine of Live Caenorhabditis elegans

Published on: April 13, 2018

Area of Science:

Gerontology and Molecular Biology
Biochemistry and Genetics

Background:

Population longevity is a complex trait influenced by genetics and environment.
Genes impact aging processes like inflammation, energy utilization, and oxidative stress.
The free radical theory of aging highlights the role of oxidative damage.

Purpose of the Study:

To review the role of paraoxonase 1 (PON1) in aging.
To explore PON1's potential involvement in human longevity.
To examine the link between PON1 genetic polymorphisms, enzyme activity, and oxidative stress defense.

Main Methods:

Literature review focusing on paraoxonase 1 (PON1) research.
Analysis of studies investigating PON1's function in aging and age-related diseases.
Examination of data on PON1 genetic variations and their functional impact.

Main Results:

PON1 protects lipids from peroxidative damage.
PON1 is implicated in atherosclerosis and age-related diseases.
Genetic variations in PON1 influence its activity and protective capabilities against oxidative stress.

Conclusions:

PON1 is a key enzyme in the context of aging.
PON1 activity and genetic factors may contribute to human longevity.
Further research into PON1's role in oxidative stress is warranted.